Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (NASDAQ: PCRX) announced on October 3, 2025 that it granted inducement equity awards on October 2, 2025 to 15 new employees under its Amended and Restated 2014 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Six employees received stock options for an aggregate of 18,000 shares (10-year term; exercise price $24.58; four-year vesting with 25% at one year). Fifteen employees received restricted stock units totaling 32,600 shares (vest annually in four equal installments beginning Oct 1, 2026). Vesting is subject to continued employment and award agreements.

BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on October 2, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Six employees received stock options to purchase an aggregate of 18,000 shares of Pacira common stock and 15 employees received restricted stock units for an aggregate of 32,600 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $24.58 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on October 1, 2026.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com

Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

FAQ

What inducement awards did Pacira (PCRX) grant on October 2, 2025?

Pacira granted options for an aggregate of 18,000 shares and 32,600 restricted stock units to 15 new employees.

What are the terms of the Pacira (PCRX) stock options granted October 2, 2025?

Options have a 10-year term, exercise price $24.58, and four-year vesting with 25% vesting after one year.

When do the restricted stock units (RSUs) granted by Pacira (PCRX) begin vesting?

The RSUs vest annually in four equal installments beginning on October 1, 2026, subject to continued employment.

Why did Pacira (PCRX) use Nasdaq Listing Rule 5635(c)(4) for these grants?

The People & Compensation Committee approved the inducement awards as a material inducement to employment without stockholder approval per Rule 5635(c)(4).

How many employees received awards in Pacira's October 2, 2025 inducement grants?

A total of 15 new employees received inducement awards; six received options and 15 received RSUs.

What conditions govern vesting for the Pacira (PCRX) inducement awards?

Vesting for both options and RSUs is contingent on continued employment and the applicable award agreement terms.